Amgen Inc. AMGN | NASDAQ
After Hours
Next Earnings: Oct 29, 2024
Company Overview:
10 Year Performance Metrics:
AMGN Dividend Payments, Yield & Share Price charts
Unlock All Reports & Research Dividend Stocks like a BOSS!
AMGN Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.
Dividend payout ration is Dividend/EPS, and indicates if company can afford to pay dividends from net income that it earned in the quarter.
Since EPS can be played with using different "accounting gymnastics", a better measure of dividends safety is Dividend to Free Cash Flow (FCF) ratio.
FCF is how much cash the company has earned each quarter, after paying all expenses not related to earnings.
Lower Ratio indicates SAFER Dividend! Ratios consistently close to, or over 100% are usually unsustainable and often indicate a dividend cut might be coming soon.
AMGN Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
AMGN Dividends Info:
AMGN Dividend History: Dates, Payments & Yield list
Below is a schedule of all AMGN dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield
| Ex-Date | Payment Date | Amount | TTM Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 08/16/2024 | 09/06/2024 | $2.250 | 2.76% | 2.8% | $321.44 |
| 05/17/2024 | 06/07/2024 | $2.250 | 0% | 0% | $0.00 |
| 05/16/2024 | 06/07/2024 | $2.250 | 2.78% | 2.86% | $314.72 |
| 02/15/2024 | 03/07/2024 | $2.250 | 2.99% | 3.11% | $289.07 |
| 11/16/2023 | 12/08/2023 | $2.130 | 3.17% | 3.17% | $269.00 |
| 08/17/2023 | 09/08/2023 | $2.130 | 3.16% | 3.23% | $263.85 |
| 05/17/2023 | 06/08/2023 | $2.130 | 3.62% | 3.79% | $225.02 |
| 02/14/2023 | 03/08/2023 | $2.130 | 3.3% | 3.53% | $241.03 |
| 11/16/2022 | 12/08/2022 | $1.940 | 2.73% | 2.73% | $283.77 |
| 08/17/2022 | 09/08/2022 | $1.940 | 3.03% | 3.1% | $250.58 |
| 05/16/2022 | 06/08/2022 | $1.940 | 3.03% | 3.18% | $243.87 |
| 02/14/2022 | 03/08/2022 | $1.940 | 3.22% | 3.46% | $224.27 |
| 11/15/2021 | 12/08/2021 | $1.760 | 3.39% | 3.39% | $207.40 |
| 08/16/2021 | 09/08/2021 | $1.760 | 2.98% | 3.05% | $231.07 |
| 05/14/2021 | 06/08/2021 | $1.760 | 2.67% | 2.8% | $251.38 |
| 02/11/2021 | 03/08/2021 | $1.760 | 2.79% | 3% | $235.04 |
| 11/13/2020 | 12/08/2020 | $1.600 | 2.7% | 2.7% | $237.36 |
| 08/14/2020 | 09/08/2020 | $1.600 | 2.61% | 2.67% | $239.71 |
| 05/15/2020 | 06/08/2020 | $1.600 | 2.54% | 2.66% | $240.20 |
| 02/13/2020 | 03/06/2020 | $1.600 | 2.67% | 2.87% | $223.04 |
| 11/14/2019 | 12/06/2019 | $1.450 | 2.65% | 2.65% | $218.50 |
| 08/14/2019 | 09/06/2019 | $1.450 | 2.85% | 2.92% | $198.87 |
| 05/16/2019 | 06/07/2019 | $1.450 | 3.26% | 3.41% | $169.92 |
| 02/14/2019 | 03/08/2019 | $1.450 | 2.9% | 3.11% | $186.68 |
| 11/15/2018 | 12/07/2018 | $1.320 | 2.74% | 2.74% | $192.45 |
| 08/16/2018 | 09/07/2018 | $1.320 | 2.6% | 2.69% | $196.44 |
| 05/16/2018 | 06/08/2018 | $1.320 | 2.84% | 3.04% | $173.80 |
| 02/14/2018 | 03/08/2018 | $1.320 | 2.66% | 2.94% | $179.52 |
| 11/16/2017 | 12/08/2017 | $1.150 | 2.69% | 2.69% | $170.77 |
| 08/15/2017 | 09/08/2017 | $1.150 | 2.62% | 2.71% | $170.04 |
| 05/15/2017 | 06/08/2017 | $1.150 | 2.69% | 2.88% | $159.97 |
| 02/13/2017 | 03/08/2017 | $1.150 | 2.48% | 2.74% | $167.66 |
| 11/14/2016 | 12/08/2016 | $1.000 | 2.73% | 2.73% | $146.42 |
| 08/15/2016 | 09/08/2016 | $1.000 | 2.17% | 2.29% | $174.58 |
| 05/13/2016 | 06/08/2016 | $1.000 | 2.35% | 2.63% | $152.35 |
| 02/11/2016 | 03/08/2016 | $1.000 | 2.38% | 2.83% | $141.46 |
| 11/12/2015 | 12/07/2015 | $0.790 | 2.09% | 2.09% | $150.98 |
| 08/13/2015 | 09/08/2015 | $0.790 | 1.77% | 1.87% | $168.58 |
| 05/12/2015 | 06/05/2015 | $0.790 | 1.77% | 2% | $158.24 |
| 02/10/2015 | 03/06/2015 | $0.790 | 1.72% | 2.07% | $152.57 |
| 11/10/2014 | 12/05/2014 | $0.610 | 1.5% | 1.5% | $163.09 |
| 08/12/2014 | 09/05/2014 | $0.610 | 1.82% | 1.93% | $126.32 |
| 05/13/2014 | 06/06/2014 | $0.610 | 1.95% | 2.2% | $110.81 |
| 02/11/2014 | 03/07/2014 | $0.610 | 1.67% | 2.01% | $121.24 |
| 11/12/2013 | 12/06/2013 | $0.470 | 1.67% | 1.67% | $112.71 |
| 08/14/2013 | 09/06/2013 | $0.470 | 1.66% | 1.76% | $106.64 |
| 05/14/2013 | 06/07/2013 | $0.470 | 1.54% | 1.74% | $107.94 |
| 02/11/2013 | 03/07/2013 | $0.470 | 1.83% | 2.21% | $84.92 |
| 11/13/2012 | 12/07/2012 | $0.360 | 1.68% | 1.68% | $85.77 |
| 08/14/2012 | 09/07/2012 | $0.360 | 1.63% | 1.72% | $83.54 |
| 05/14/2012 | 06/07/2012 | $0.360 | 1.82% | 2.05% | $70.20 |
| 02/13/2012 | 03/07/2012 | $0.360 | 1.35% | 2.11% | $68.20 |
| 11/15/2011 | 12/08/2011 | $0.280 | 0.99% | 1.98% | $56.59 |
| 08/16/2011 | 09/08/2011 | $0.280 | 0.55% | 2.18% | $51.27 |
Get the best Dividend Stock Research Tools:
Projected Future Returns & Dividends for AMGN
Based on past 10-year performance, here are AMGN growth metrics:Using AMGN CAGR metrics, we can estimate, that your initial $10000 investment, over next 10 years ago, should grow with dividends being reinvested (DRIP) as follows:
Share price CAGR of +8.89%
Dividend CAGR of +13.94%
| AMGN | |
|---|---|
| Current Price | $337.38 |
| Start Shares | 29.64 |
| Start Value | $10,000 |
| After 10 years: | |
| Final Share Count | 41.17 |
| Dividends Payment | $8.30 |
| Annual Dividends | $1,367 |
| Yield on cost | 13.67% |
| Share Price | $725.89 |
| Total Dividends | $6,199 |
| Final Value | $29,886 |
NOTE: Above numbers are our estimate based on AMGN's Dividend and Price CAGR over past 10 years.
These numebrs should only be considered as "potential future returns"! These numbers assume DRIP (reinvesting dividends).
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Amgen Inc. (AMGN) had its IPO on 1983-06-17, and is trader on NASDAQ stock exchange.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN website: https://www.amgen.com
